Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fingolimod.

Megan H Hyland1, Jeffrey A Cohen1

  • 1Neurological Institute, Cleveland Clinic, Cleveland, Ohio.

Neurology. Clinical Practice
|February 15, 2018
PubMed
Summary

Fingolimod offers an effective oral treatment for relapsing-remitting multiple sclerosis (MS). While generally safe, understanding its complex mechanism and potential adverse effects is crucial for widespread clinical adoption.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

Progressive disability but survival advantage in anti-Hu/ANNA1 paraneoplastic neurological syndromes.

Journal of neurology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Effect of Botulinum Toxin Injection Intervals on the Irreversibility of Targeted Muscle Paralysis: An Electromyographic Study.

Aesthetic surgery journal·2026
Same author

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants.

Annals of clinical and translational neurology·2026
Same author

Paramagnetic rim lesions on 7T MRI after autologous hematopoietic cell transplantation.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Relapsing-remitting multiple sclerosis (MS) management.
  • Introduction of fingolimod as an oral therapy.
  • Comparison with existing injectable MS treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of fingolimod in MS.
  • To discuss the place of fingolimod in the MS treatment algorithm.
  • To explore challenges and potential for increased use of fingolimod.

Main Methods:

  • Review of clinical trial data for fingolimod.
  • Analysis of safety and tolerability profiles.
  • Discussion of mechanism of action and clinical practice experience.

Main Results:

  • Fingolimod demonstrates potent efficacy and an oral administration route.
  • Generally good safety and tolerability observed, but adverse effects are noted.
  • Direct switching from interferon-β or glatiramer acetate is possible.

Conclusions:

  • Fingolimod is a promising oral therapy for MS, offering convenience.
  • Further clinical experience is needed to fully understand its long-term safety and efficacy.
  • Logistical issues and understanding adverse effects are key to broader adoption.

Related Experiment Videos